期刊
FRONTIERS IN PHARMACOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.601751
关键词
anti-obesity; adipogenesis; lipolysis; browning of white adipose tissue; insulin sensitivity
资金
- Fundamental Research Funds for the Central Universities [3332019156]
- National Natural Sciences Foundation of China [81891012]
- Drug Innovation Major Project [2018ZX09711001-009]
- Key laboratory project of Chinese Academy of Medical Sciences [2018PT35030]
- National Key Research and Development Project [2017YFC1702504]
The increasing prevalence of obesity worldwide has led to limited options for effective and safe anti-obesity drugs. Notoginsenosides, derived from traditional Chinese medicine Panax notoginseng, show potential in treating obesity by reducing lipid synthesis and improving insulin sensitivity. Further research is still needed to fully understand the effects and mechanisms of notoginsenosides in combating obesity.
The prevalence of individuals who are overweight or obese is rising rapidly globally. Currently, majority of drugs used to treat obesity are ineffective or are accompanied by obvious side effects; hence, the options are very limited. Therefore, it is necessary to find more effective and safer anti-obesity drugs. It has been proven in vivo and in vitro that the active ingredient notoginsenosides isolated from traditional Chinese medicine Panax notoginseng (Burk.) F. H. Chen exhibits anti-obesity effects. Notoginsenosides can treat obesity by reducing lipid synthesis, inhibiting adipogenesis, promoting white adipose tissue browning, increasing energy consumption, and improving insulin sensitivity. Although notoginsenosides are potential drugs for the treatment of obesity, their effects and mechanisms have not been analyzed in depth. In this review, the anti-obesity potential and mechanism of action of notoginsenosides were analyzed; thus laying emphasis on the timely prevention and treatment of obesity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据